In the ever-evolving landscape of telemedicine, a new trend has emerged that raises more questions than it answers. Recently, several online telemedicine companies have started offering compounded oral versions of tirzepatide. But is this approved? Is it effective? Where did this come from? Let’s dig deeper.
Only very recently, Lexaria Bioscience was awarded the ability to study and alter tirzepatide. Lexaria uses a patented process called DehydraTECH™ to extract the active pharmaceutical ingredient (API) and add fat-friendly lipid molecules to the medication. This process is designed to increase the absorption and bioavailability of the product. While this sounds promising, it's important to note that Lexaria's current work is still in the very early stages, involving small-scale tests.
When discussing oral peptides, Rybelsus is the only approved oral GLP-1 medication currently on the market. The highest dose, set to be available later this year, is 50 mg daily. To put this in perspective, 50 mg of oral semaglutide daily equates to 350 mg weekly. This dose achieves similar weight loss results as 2.4 mg of Wegovy weekly, which means 350 mg of semaglutide is needed to match the efficacy of just 2.4 mg of Wegovy.
If we extrapolate this logic to tirzepatide, if one were to achieve the same weight loss results as the 15 mg version of tirzepatide (such as those in Mounjaro & Zepbound), the required daily dose would be approximately 312 mg. This staggering amount raises questions about the feasibility and practicality of these oral offerings.
The surge in telemedicine has undoubtedly opened doors to more accessible healthcare. However, it has also created an environment where some companies push the boundaries of legality and safety. The compounded oral tirzepatide currently being offered by some telemedicine companies has not undergone complete clinical trials, making its safety and efficacy highly questionable.
It’s essential to be vigilant when navigating these waters. Always consult with reputable telemedicine companies and be wary of those offering medications that haven’t been thoroughly vetted. The convenience of telemedicine should never come at the cost of safety and efficacy.
As the telemedicine industry continues to grow, so too does the need for caution and due diligence. While innovations like Lexaria’s DehydraTECH™ offer potential advancements in drug delivery, it is only in early testing phases. It is crucial to approach new and unproven treatments with a healthy dose of skepticism. Always ensure that you are consulting with credible sources and making informed decisions about your health.
For more detailed information about Lexaria Bioscience and their ongoing research, you can visit their [official website](https://ir.lexariabioscience.com/news-events/press-releases/detail/252/lexaria-awards-contract-for-third-glp-1-human-pilot-study).
Stay informed, stay safe, and always stay in touch with the latest news by getting alerts at onthepen.com/emails
Comments